Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in the Netherlands

Acta Oncologica

Volumn 51, Issue 1, 2012, Pages 57-64

  Van Gils, Chantal W M ^a   Koopman, Miriam ^b   Mol, Linda ^c   Redekop, William K ^a   Uyl De Groot, Carin A ^a   Punt, Cornelis J A ^d  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c Integraal Kankercentrum Oost   (Netherlands)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

AGE DISTRIBUTION; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; COLON CANCER; DISEASE FREE SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NETHERLANDS; POPULATION RESEARCH; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; COLONIC NEOPLASMS; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GUIDELINE ADHERENCE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; NETHERLANDS; ORGANOPLATINUM COMPOUNDS; PRACTICE GUIDELINES AS TOPIC; REGISTRIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 83455181699     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2011.633930     Document Type: Article

References (25)

1. Parkin DM., Bray F., Ferlay J., Pisani P. Global cancer statistics., 2002. CA Cancer J Clin 2005;55:74-108.
2. Obrand DI., Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997;40:15-24. (Pubitemid 27056393)
3. Moertel CG., Fleming TR., Macdonald JS., Haller DG., Laurie JA., Goodman PJ., et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8. (Pubitemid 20042739)
4. Andre T., Boni C., Mounedji-Boudiaf L., Navarro M., Tabernero J., Hickish T., et al. Oxaliplatin., fluorouracil., and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51. (Pubitemid 38702845)
5. Twelves C., Wong A., Nowacki MP., Abt M., Burris H., 3rd., Carrato A., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704. (Pubitemid 41007824)
6. Punt CJ. New options and old dilemmas in the treatment of patients with advanced colorectal cancer. Ann Oncol 2004;15:1453-9. (Pubitemid 39409733)
7. Shields AF., Zalupski MM., Marshall JL., Meropol NJ. Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: A phase II trial. Cancer 2004;100:531-7. (Pubitemid 38124770)
8. Cassidy J., Tabernero J., Twelves C., Brunet R., Butts C., Conroy T., et al. XELOX (capecitabine plus oxaliplatin]: Active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004;22:2084-91. (Pubitemid 41095141)
9. Kuebler JP., Wieand HS., O'Connell MJ., Smith RE., Colangelo LH., Yothers G., et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol 2007;25:2198-204. (Pubitemid 46954643)
10. Schmoll HJ., Cartwright T., Tabernero J., Nowacki MP., Figer A., Maroun J., et al. Phase III trial of capecitabine plus oxali-platin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1,864 patients. J Clin Oncol 2007;25: 102-9. (Pubitemid 350003057)
11. Andre T., Boni C., Navarro M., Tabernero J., Hickish T., Topham C., et al. Improved overall survival with oxaliplatin., fluorou-racil., and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC Trial. J Clin Oncol 2009; 27:3109-16.
12. Labianca R., Nordlinger B., Beretta GD., Brouquet A., Cervantes A., ESMO Guidelines Working Group. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis., adjuvant treatment and follow-up. Ann Oncol 2010;21(Suppl 5): v70-7.
13. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?. Lancet 2005;365:82-93. (Pubitemid 40082150)
14. Silverman SL. From randomized controlled trials to observational studies. Am J Med 2009;122:114-20.
15. Charlson ME., Pompei P., Ales KL., MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40: 373-83. (Pubitemid 17055592)
16. Lemmens VE., van Halteren AH., Janssen-Heijnen ML., Vreugdenhil G., Repelaer van Driel OJ., Coebergh JW. Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status., gender., and comorbidity. Ann Oncol 2005;16:767-72. (Pubitemid 40767098)
17. Kahn KL., Adams JL., Weeks JC., Chrischilles EA., Schrag D., Ayanian JZ., et al. Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. JAMA 2010;303:1037-45.
18. Goldberg RM., Tabah-Fisch I., Bleiberg H., de Gramont A., Tournigand C., Andre T., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006;24:4085-91. (Pubitemid 46622283)
19. McCleary JN., Meyerhardt J., Green E,Yothers G., de Gramont A., Van Cutsem E., et al. Impact of older age on the efficacy of newer adjuvant therapies in > 12,500 patients (pts) with stage II/III colon cancer: Findings from the ACCENT Database (abstract). J Clin Oncol 2009;27(170s).
20. Haller DG., Cassidy J., Tabernero J., Maroun JA., De Braud FG., Price TJ., et al. Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin verus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS). (abstract). Presented at the 2010 ASCO gastrointestinal cancers Symposium., Orlando., FL., January 22. 2010.
21. Etzioni DA., El-Khoueiry AB., Beart RW., Jr. Rates and predictors of chemotherapy use for stage III colon cancer: A systematic review. Cancer 2008;113:3279-89.
22. van Steenbergen LN., Rutten HJ., Creemers GJ., Pruijt JF., Coebergh JW., Lemmens VE. Large age and hospital-dependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands. Ann Oncol 2010;21:1273-8.
23. Arkenau HT., Arnold D., Cassidy J., Diaz-Rubio E., Douillard JY., Hochster H., et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: A pooled analysis of randomized trials. J Clin Oncol 2008;26:5910-7.
24. Haller D., Tabernero J., Maroun J., De Braud F., Price T., Van Cutsem E., et al. First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/ LV for stage III colon cancer (NO16968/XELODA study). Presented at the joint ECCO/ESMO multidisciplinary congress., (abstr 5LBA)., Berlin., 20-24 September., 2009.
25. Mol L., Punt CJA., van Gils CWM., Ottevanger PB., Koopman M.Trial participation in a multicentre phase III trial (CAIRO) in advanced colorectal cancer patients in The Netherlands., and a comparison of outcome between trial and non-trial patients. (abstract 581PD). Presented at the 35th ESMO Congress Milan., Italy 8-12 October., 2010.